Trial Profile
A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2014
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2005 New trial record.